Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BAY3723113

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Hypertrophic CardiomyopathyActive, not recruiting

Obstructive Hypertrophic CardiomyopathyPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Obstructive Hypertrophic Cardiomyopathy

NCT07023341

Clinical

Trials by Indication[1]

Obstructive Hypertrophic Cardiomyopathy1 trial

A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Active, not recruiting· Bayer logo

Bayer·Phase 3·NCT07023341·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BAY3723113. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAY3723113 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAY3723113. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Related News